At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AKTX Akari Therapeutics PLC
Market Closed 09-04 16:00:00 EDT
11.47
+0.63
+5.81%
盘后12.95
+1.48+12.90%
19:42 EDT
High11.82Low10.17Vol108.91K
Open10.41D1 Closing10.84Amplitude15.22%
Mkt Cap22.33MTradable Cap7.97MTotal Shares1.95M
T/O1.22MT/O Rate15.68%Tradable Shares694.50K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading
MT Newswires Live  ·  08-31
European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading
Akari Therapeutics Participates in Virtual Investor “Why Now” On-Demand Conference Webcast
Reuters  ·  08-27
Akari Therapeutics Participates in Virtual Investor “Why Now” On-Demand Conference Webcast
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
MT Newswires Live  ·  08-26
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Head Lower in Tuesday Trading
MT Newswires Live  ·  08-18
European Equities Traded in the US as American Depositary Receipts Head Lower in Tuesday Trading
Akari Therapeutics - Ph1 Payload Shows Potential to Overcome Payload-Specific Resistance
THOMSON REUTERS  ·  08-18
Akari Therapeutics - Ph1 Payload Shows Potential to Overcome Payload-Specific Resistance
Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity in Urothelial Cancer Preclinical Models
THOMSON REUTERS  ·  08-18
Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity in Urothelial Cancer Preclinical Models
Akari Therapeutics - Continues to Advance Ind-Enabling Activities for Aktx-101 with Goal of Initiating Phase 1 Clinical Trial in Mid-2027
THOMSON REUTERS  ·  08-18
Akari Therapeutics - Continues to Advance Ind-Enabling Activities for Aktx-101 with Goal of Initiating Phase 1 Clinical Trial in Mid-2027
Akari Therapeutics - Developing Aktx-102 ADC Targeting Ceacam5 in Multiple Solid Tumors
THOMSON REUTERS  ·  08-18
Akari Therapeutics - Developing Aktx-102 ADC Targeting Ceacam5 in Multiple Solid Tumors
Akari Therapeutics Says AKTX-101 Shows Anti-Tumor Activity in Preclinical Urothelial Cancer Models
Reuters  ·  08-18
Akari Therapeutics Says AKTX-101 Shows Anti-Tumor Activity in Preclinical Urothelial Cancer Models
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
MT Newswires Live  ·  08-17
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
European Equities Traded in the US as American Depositary Receipts Track Lower in Friday Trading
MT Newswires Live  ·  08-14
European Equities Traded in the US as American Depositary Receipts Track Lower in Friday Trading
UK's Akari Therapeutics Q2 Net Loss Widens on Higher R&D for AKTX-101
Reuters  ·  08-14
UK's Akari Therapeutics Q2 Net Loss Widens on Higher R&D for AKTX-101
Akari Therapeutics PLC Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-14
Akari Therapeutics PLC Reports Results for the Quarter Ended June 30 - Earnings Summary
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of Aktx-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
THOMSON REUTERS  ·  08-14
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of Aktx-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
Press Release: Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
Dow Jones  ·  08-14
Press Release: Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
Akari Net Loss Widens to $4.81 Million in Q2 FY26; Operating Loss Rises to $4.6 Million
Reuters  ·  08-14
Akari Net Loss Widens to $4.81 Million in Q2 FY26; Operating Loss Rises to $4.6 Million
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
MT Newswires Live  ·  08-11
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
European Equities Traded in the US as American Depositary Receipts Edge Higher in Monday Trading
MT Newswires Live  ·  08-10
European Equities Traded in the US as American Depositary Receipts Edge Higher in Monday Trading
Akari Therapeutics PLC Expected to Post a Loss of $1.40 a Share - Earnings Preview
Reuters  ·  08-08
Akari Therapeutics PLC Expected to Post a Loss of $1.40 a Share - Earnings Preview
Akari Therapeutics Enters Research Collaboration with WhiteHawk Therapeutics on Dual-Payload ADCs
Reuters  ·  08-04
Akari Therapeutics Enters Research Collaboration with WhiteHawk Therapeutics on Dual-Payload ADCs

Introduction

Company Name.
Akari Therapeutics PLC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
Issue price:
--